论文部分内容阅读
本文报告用重组人促红细胞生成素(rHuEPO)治疗再生障碍性贫血(AA)37例的临床效果。37例中可资评价者29例,男16例,女13例,年龄均为15岁以上。按日本厚生省造血障碍调研班制定的AA重症程度分级标准:轻度2例,中度11例,重度16例。病因:肝炎后AA2例,特发性再障27例。用该疗法前病程分别为1～254个月(中数71个月)。20例用rHuEPO前曾接受男性激素等治疗。用该药前8
This article reports the clinical efficacy of recombinant human erythropoietin (rHuEPO) in the treatment of 37 patients with aplastic anemia (AA). Among the 37 cases, 29 were evaluable, 16 were males and 13 were females, all of whom were over 15 years of age. According to Japan’s Ministry of Health, hematopoietic disorders research class developed AA grade grading standards: mild in 2 cases, moderate in 11 cases, severe in 16 cases. Cause: AA2 after hepatitis, idiopathic aplastic anemia in 27 cases. With the course of the disease before treatment were 1 to 254 months (median 71 months). 20 patients received rHuEPO before treatment with male hormone. Use this medicine before 8